Get the Stockscreener App
15.33
2.48%
-0.39
Janux Therapeutics Inc stock is traded at $15.33, with a volume of 550.01K.
It is down -2.48% in the last 24 hours and up +4.71% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$15.72
Open:
$15.81
24h Volume:
550.01K
Relative Volume:
0.52
Market Cap:
$934.89M
Revenue:
$13.73M
Net Income/Loss:
$-114.48M
P/E Ratio:
-8.3234
EPS:
-1.8418
Net Cash Flow:
$-78.49M
1W Performance:
-5.72%
1M Performance:
+4.71%
6M Performance:
+3.51%
1Y Performance:
-40.97%
1-Day Range:
$15.24
$15.87
1-Week Range:
$15.24
$16.53
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.33 | 934.89M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership - Moomoo
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W - Moomoo
Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily
Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key ResistanceIPO Entry Watch - dars.gov.et
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - MSN
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st
Janux Therapeutics Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises 6%Dividend Cut Risk - dars.gov.et
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Discipline and Rules-Based Execution in JANX Response - Stock Traders Daily
Janux Therapeutics (JANX) Gains 2.47% as Shares Hold Above Key Support LevelDiagonal Spread Trade - dars.gov.et
JANX Forecast — Price Target — Prediction for 2027 - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX) - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (BX:JANX) - TradingView
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia
Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Janux Therapeutics announces departure of chief medical officer - Investing.com
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan
Janux Therapeutics (JANX) Gains Modestly Amid Biotech Sector CautionSynthetic Long - dars.gov.et
JANX Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Clinical ProgressAnalyst Coverage Count - dars.gov.et
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Janux Therapeutics Inc (JANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics Inc (JANX) Institutional Confidence - TradingKey
Top Cybin (HELP) Competitors 2026 - MarketBeat
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):